One study evaluated IACS‐010759 (OPi), a mitochondrial oxidative phosphorylation complex I inhibitor, against MAPKi‐resistant BRAF‐mutant melanomas, demonstrating significant antitumor activity in vitro and in vivo [50]. Here, BRAF is linked to melanoma.